philip philip, md on stivarga (regorafenib) dosage in 2nd line treatment of mcrc
Published 8 years ago • 194 plays • Length 0:56
Download video MP4
Download video MP3
Similar videos
-
0:51
philip philip, md explains how to integrate regorafenib and trifluridine for 2nd line mcrc treatment
-
1:47
alan venook, md relays the optimal dose for regorafenib (stivarga) in the 2nd line treatment of mcrc
-
1:27
tanios bekaii-saab, md, comments on dosing regorafenib (stivarga) in 3rd line treatment of mcrc
-
1:36
philip philip, md, shares his perspective on using tas-102 and regorafenib in crc patients
-
0:25
alan venook, md on integrating regorafenib and trifluridine into the 2nd line treatment of mcrc
-
1:35
philip philip, md, on integrating immunotherapy into existing treatment regimens for crc patients
-
3:00
philip philip, md, on the phase 2 study comparing chemo with or without veliparib in pancreas
-
0:42
dr. bendell on the future of regorafenib for patients with crc
-
2:21
philip philip, md, on what we’ve learned about the duration of therapy in the adjuvant crc setting
-
1:09
survival benefit confirmed in real-life analysis of second-line regorafenib in hcc
-
2:04
philip philip, md, shares opinion on treatment of a brca pancreatic cancer patient
-
2:19
philip philip, md, on the outcomes of the polo study and its importance to physicians
-
2:42
philip philip, md discusses phase 3 calgb/swog 80405 study outcomes
-
4:42
philip philip md, phd, frcp, on the apact trial in surgically resected pancreatic adenocarcinoma
-
1:36
optimal dosing of regorafenib in colorectal cancer
-
0:57
philip philip, md, provides thoughts on the role of parp inhibitors in advanced pancreatic cancer
-
1:15
philip philip, md, on the lenvatinib data in patients with unresectable hcc presented at asco 2017
-
2:03
philip philip md, phd, frcp, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer
-
0:49
dr. bendell on remaining questions with regorafenib in hcc
Clip.africa.com - Privacy-policy